Ranolazine
DrugRanolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Other names: Ranexa
NCT Number: NCT01839110
This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension specific therapies but with right ventricular dysfunction (RVEF <45%) would improve their outcome. This study is accompanied by a baseline comparison of the metabolic profiling/microRNA/iPS cells of subjects with and without right ventricular dysfunction.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
University of Maryland, Baltimore, Maryland, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Other names: Ranexa
Placebo by mouth twice per day for a total of 26 weeks.
Time frame: 6 months
right ventricular ejection fraction by cardiac MRI
University of Pennsylvania
Other
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00011648
Anemia, Anemia, Hemolytic
Washington D.C., District of Columbia, United States
View Trial DetailsNCT00678821
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT03629340
Cardiovascular Diseases, Heart Diseases
San Francisco, California, United States
View Trial DetailsNCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial Details